Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery
Completed · Not applicable
Conditions studied: Osteoarthritis, Knee
In brief
The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total knee arthroplasty, as compared to standard of care analgesia.
Key facts
- Study ID
- NCT02219087
- Run by
- OhioHealth
- People needed
- 60
- Starts
- 2014-08-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2018-01-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- At least 18 years of age
- Scheduled to undergo total knee arthroplasty (TKA) performed by the principal investigator
You may not qualify if…
- Age <18 years
- Pregnant or breastfeeding
- Non-English-speaking
- Unable to give informed consent
- Patients admitted from or discharged to a medical facility (due to likelihood of limited mobility and/or required minimum lengths of stay, confounding primary outcome), including other hospitals, skilled nursing facilities, long-term acute care hospitals, etc.
- Patients unable to complete a device-assisted 140 foot walk at baseline
- Patients with contraindication(s) to any bupivacaine or ropivacaine formulation, to nerve blocks or any of the local agents used (IV morphine, ketorolac, or methylprednisolone).
- Patients on a long-acting maintenance opioid prior to admission for surgery (e.g., methadone, oxycontin)
- Patients undergoing simultaneous bilateral TKAs, as this would increase the dose of Exparel per patient (we are limited to one dose per patient)
Where it is running
- OhioHealth Grant Medical Center Bone and Joint Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.